Osong Public Health and Research Perspectives

Original Articles

Impact of Corporate Governance on Research and Development Investment in the Pharmaceutical Industry in South Korea: Munjae Lee; Osong Public Health Res Perspect. 2015;6(4):249-255. Published online August 31, 2015; DOI: https://doi.org/10.1016/j.phrp.2015.07.003

2,368 View
18 Download
3 Citations

Objectives
The purpose of this study is to analyze the influence of the corporate governance of pharmaceutical companies on research and development (R&D) investment.
Methods
The period of the empirical analysis is from 2000 to 2012. Financial statements and comments in general, and internal transactions were extracted from TS-2000 of the Korea Listed Company Association. Sample firms were those that belong to the medical substance and drug manufacturing industries. Ultimately, 786 firm-year data of 81 firms were included in the sample (unbalanced panel data).
Results
The shareholding ratio of major shareholders and foreigners turned out to have a statistically significant influence on R&D investment (p < 0.05). No statistical significance was found in the shareholding ratio of institutional investors and the ratio of outside directors.
Conclusion
The higher the shareholding ratio of the major shareholders, the greater the R&D investment. There will be a need to establish (or switch to) a holding company structure. Holding companies can directly manage R&D in fields with high initial risks, and they can diversify these risks. The larger the number of foreign investors, the greater the R&D investment, indicating that foreigners directly or indirectly impose pressure on a manager to make R&D investments that bring long-term benefits.

Citations

Citations to this article as recorded by

EFFECT OF CORPORATE GOVERNANCE PRACTICES ON R&D AND INNOVATION COSTS: A CASE STUDY ON BORSA İSTANBUL
Hüseyin Ali KUTLU, Bekir GEREKAN
Muhasebe ve Vergi Uygulamaları Dergisi.2021; 14(3): 967. CrossRef
Corporate governance and the environment in the health sector: Systematic literature review
Isabel Cristina Panziera Marques, Zélia Maria da Silva Serrasqueiro Teixeira, Fernanda Maria Duarte Nogueira
Journal of Governance and Regulation.2020; 9(2): 8. CrossRef
Differentiation of innovation strategies based on pharmaceutical licensing agreements: Insight from Korean pharmaceutical firms
Chie Hoon Song, Jens Leker
Technology Analysis & Strategic Management.2019; 31(2): 169. CrossRef

Analysis on Time-Lag Effect of Research and Development Investment in the Pharmaceutical Industry in Korea: Munjae Lee, Mankyu Choi; Osong Public Health Res Perspect. 2015;6(4):241-248. Published online August 31, 2015; DOI: https://doi.org/10.1016/j.phrp.2015.07.001

2,385 View
13 Download
13 Citations

Abstract PDF

Objectives
The aim of this study is to analyze the influence of the research and development (R&D) investment of pharmaceutical companies on enterprise value.
Methods
The period of the empirical analysis is from 2000 to 2012, considering the period after the influence of the financial crisis. Financial statements and comments in general and internal transactions were extracted from TS-2000 of the Korea Listed Company Association, and data related to stock price were extracted from KISVALUE-III of National Information and Credit Evaluation Information Service Co., Ltd. STATA 12.0 was used as the statistical package for panel analysis.
Results
In the pharmaceutical firms, the influence of the R&D intensity with regard to Tobin's q was found to be positive. However, only the R&D expenditure intensities of previous years 2 and 5 (t–2 and t–5, respectively) were statistically significant (p < 0.1), whereas those of previous years 1, 3, and 4 years (t–1, t–3, and t–4, respectively) were not statistically significant.
Conclusion
R&D investment not only affects the enterprise value but is also evaluated as an investment activity that raises the long-term enterprise value. The research findings will serve as valuable data to understand the enterprise value of the Korea pharmaceutical industry and to strengthen reform measures. Not only should new drug development be made, but also investment and support should be provided according to the specific factors suitable to improve the competitiveness of each company, such as generic, incrementally modified drugs, and biosimilar products.

Citations

Citations to this article as recorded by

R&D activity and firm performance: mapping the field
Kseniia Boiko
Management Review Quarterly.2022; 72(4): 1051. CrossRef
Pharmaceutical industry in export marketing: a closer look at competitiveness
Mehdi Mohammadzadeh, Nima Bakhtiari, Reza Safarey, Tayebeh Ghari
International Journal of Pharmaceutical and Health.2021; 13(3): 331. CrossRef
The effect of intangible assets on sustainable growth and firm value – Evidence on intellectual capital investment in companies listed on Bucharest Stock Exchange
Catalin Ionita, Elena Dinu
Kybernetes.2021; 50(10): 2823. CrossRef
AR-GE GİDERLERİ İLE KÂRLILIK VE BÜYÜME ARASINDA NEDENSELLİK İLİŞKİSİ: BIST ÜZERİNE BİR İNCELEME
Mehmet DİKİCİ, Kadir GÜRDAL
Muhasebe ve Vergi Uygulamaları Dergisi.2021; 14(3): 1193. CrossRef
R&D Investments, Debt Capital, and Ownership Concentration: A Three-Way Interaction and Lag Effects on Firm Performance in China's Pharmaceutical Industry
Chih-Yi Su, Yao-Ning Guo, Kuang-Cheng Chai, Wei-Wei Kong
Frontiers in Public Health.2021;[Epub] CrossRef
R&D SPENDING AND FINANCIAL PERFORMANCE: AN INVESTIGATION IN AN EMERGING MARKET
Nasıf ÖZKAN
International Journal of Management Economics and .2021;[Epub] CrossRef
The persistence of current market valuation of future capital investment
Nancy Beneda
Journal of Corporate Accounting & Finance.2020; 31(3): 163. CrossRef
Sustainability assessment of universities as small-scale urban systems: A comparative analysis using Fisher Information and Data Envelopment Analysis
Ning Ai, Marc Kjerland, Cynthia Klein-Banai, Thomas L. Theis
Journal of Cleaner Production.2019; 212: 1357. CrossRef
Analysing future change in the EU's energy innovation system
Yeong Jae Kim, Charlie Wilson
Energy Strategy Reviews.2019; 24: 279. CrossRef
A review of three years' experience of the first pharmacometrics company in Korea
So Jin Lee, Sangil Jeon
Translational and Clinical Pharmacology.2019; 27(4): 149. CrossRef
The impact of inter-industry R&D technology spillover on carbon emission in China
Jianling Jiao, Yufei Yang, Yu Bai
Natural Hazards.2018; 91(3): 913. CrossRef
Characteristics of Corporate R&D Investment in Emerging Markets: Evidence from Manufacturing Industry in China and South Korea
Jian Xu, Jae-Woo Sim
Sustainability.2018; 10(9): 3002. CrossRef
R&D Investments, EPO Patent Applications and the Economic Heterogeneity within the EU
Zuzana Potužáková, Jan Öhm
Review of Economic Perspectives.2018; 18(2): 177. CrossRef

First
Prev
Page of 1
Next
Last

Search